0001615898-19-000001.txt : 20190104 0001615898-19-000001.hdr.sgml : 20190104 20190104105509 ACCESSION NUMBER: 0001615898-19-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190104 DATE AS OF CHANGE: 20190104 EFFECTIVENESS DATE: 20190104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pear Therapeutics, Inc. CENTRAL INDEX KEY: 0001615898 IRS NUMBER: 463597074 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-329643 FILM NUMBER: 19508740 BUSINESS ADDRESS: STREET 1: 55 TEMPLE PL., 3RD FLOOR CITY: BOSTON STATE: MA ZIP: 02111 BUSINESS PHONE: 6469322774 MAIL ADDRESS: STREET 1: 55 TEMPLE PL., 3RD FLOOR CITY: BOSTON STATE: MA ZIP: 02111 D 1 primary_doc.xml X0708 D LIVE 0001615898 Pear Therapeutics, Inc. 200 State Street 13th Floor BOSTON MA MASSACHUSETTS 02109 6179257848 DELAWARE None None Corporation true Corey McCann c/o Pear Therapeutics 200 State Street, 13th Floor Boston MA MASSACHUSETTS 02109 Executive Officer Director Andrew Schwab c/o Pear Therapeutics 200 State Street, 13th Floor Boston MA MASSACHUSETTS 02109 Director Zack Lynch c/o Pear Therapeutics 200 State Street, 13th Floor Boston MA MASSACHUSETTS 02109 Director Timothy Petersen c/o Pear Therapeutics 200 State Street, 13th Floor Boston MA MASSACHUSETTS 02109 Director Hongjie Hu c/o Pear Therapeutics 200 State Street, 13th Floor Boston MA MASSACHUSETTS 02109 Director Christopher Guiffre c/o Pear Therapeutics 200 State Street, 13th Floor Boston MA MASSACHUSETTS 02109 Executive Officer Alex Waldron c/o Pear Therapeutics 200 State Street, 13th Floor Boston MA MASSACHUSETTS 02109 Executive Officer Yuri Maricich c/o Pear Therapeutics 200 State Street, 13th Floor Boston MA MASSACHUSETTS 02109 Executive Officer Jeremy Gilbert c/o Pear Therapuetics 200 State Street, 13th Floor Boston MA MASSACHUSETTS 02109 Executive Officer Other Health Care Decline to Disclose 06b false 2018-12-21 false true false 0 64999912 64344915 654997 false 21 0 0 0 false Pear Therapeutics, Inc. /s/ Christopher Guiffre Christopher Guiffre Chief Financial Officer 2019-01-04